The Importance of Ghrelin for Glucose Metabolism After Sleeve Gastrectomy

The overall aim is to delineate the contribution of ghrelin to glucose tolerance after sleeve gastrectomy. The hypothesis is that decreased concentration of ghrelin after SG is of importance for improved insulin secretion and glucose tolerance seen after SG. The expectation is therefore that infusion of ghrelin will impair insulin secretion and glucose tolerance compared with a control day without ghrelin infusion.

Study Overview

• Status: Completed
• Conditions: Glucose Metabolism Disorders; Bariatric Surgery Candidate
• Intervention / Treatment: Other: Placebo; Other: Ghrelin

Detailed Description

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are bariatric procedures. Overwhelming evidence support bariatric surgery as the most effective treatment for severe obesity and related metabolic comorbidities, particularly type 2 diabetes mellitus.

The mechanisms of improved glycaemic control after SG are not fully understood and differ from those of RYGB. Interestingly, there is demonstrated a markedly lower secretion of the orexigenic hormone ghrelin after SG compared with both RYGB and unoperated obese controls. Hence, the decreased level of ghrelin could be of major importance in relation to the improved glucose tolerance after SG.

Ghrelin is secreted from the gastric mucosa in the fasting state and decreases in response to food intake. Administration of exogenous ghrelin reduces insulin sensitivity and glucose tolerance in healthy humans and contributes to hyperglycaemia. In accordance, ghrelin receptor knockout in mice improves glucose sensitivity and enhances glucose-stimulated insulin secretion.

On this background the investigators hypothesize that the markedly reduced secretion of ghrelin after SG could therefore be of particularly importance for the improved glucose tolerance after this procedure.

This present study is complementary to an on-going study in SG operated subjects, where the role of ghrelin for appetite and insulin secretion during a mixed meal followed by an ad libitum meal are investigated. In the present study the effect of ghrelin on insulin secretion and insulin sensitivity is thoroughly investigated using methods eliminating the effect of other hormones on glucose metabolism.

Ghrelin will be infused in physiological doses aiming for plasma concentration after SG resembling the pre-operative plasma concentrations.

Specific aim is to evaluate the effect of ghrelin on both alpha and beta cell function as well as on liver and peripheral insulin sensitivity in individuals with SG using matched controls. The subjects will be investigated with both glucose and glycerol tracers, IVGTT and a hyperinsulinemic euglycaemic clamp.

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Hvidovre, Denmark, 2650
    • Hvidovre Universitets Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Sleeve gastrectomy-operated > 12 months prior to inclusion
• Weight stable (+/- 3 kg during the last 3 months)
• Fasting glucose < 7,0 mmol/l / HbA1c < 48 mmol/mol pre- and postoperative
• Signed written informed consent

Exclusion Criteria:

• Pregnancy or breastfeeding.
• Haemoglobin < 6,5 mM.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Gastric sleeve operated; 12 subjects with normal glucose tolerance (NGT) operated with SG minimum 12 month earlier	Other: Placebo; Saline infusion; Other: Ghrelin; Ghrelin infusion
Placebo Comparator: Matched control group; 12 weight-matched unoperated subjects with NGT	Other: Placebo; Saline infusion; Other: Ghrelin; Ghrelin infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The difference in disposition index between the two study days with and without ghrelin in fusion in the SG operated group	The first phase insulin response will be related to the ambient insulin sensitivity by calculating the disposition index (FPIR x M-value).	0-180 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The difference in first phase insulin response (FPIR) between the two study days with and without ghrelin in fusion in the SG operated group	Estimation of beta-cell function, calculated from insulin secretion rate using c-peptid and deconvolution from 0-10 min.	0-10 minutes (IVGTT)
The difference in Insulin sensitivity (M-value) between the two study days with and without ghrelin in fusion in the SG operated group	When a steady state is reached at the end of the clamp, the glucose infusion rate represents insulin-mediated glucose uptake by the body.	160-180 minutes (the end of the clamp)

Collaborators and Investigators

• Sponsor: Hvidovre University Hospital
• Collaborators: Institute of Biomedical Sciences, SUND, University of Copenhagen

Study record dates

Study Major Dates

• Study Start (Actual): January 14, 2022
• Primary Completion (Actual): June 26, 2023
• Study Completion (Actual): June 26, 2023

Study Registration Dates

• First Submitted: December 28, 2021
• First Submitted That Met QC Criteria: December 28, 2021
• First Posted (Actual): January 12, 2022

Study Record Updates

• Last Update Posted (Actual): November 1, 2023
• Last Update Submitted That Met QC Criteria: October 31, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Ghrelin; Glucose metabolism; Gastric sleeve
• Additional Relevant MeSH Terms: Metabolic Diseases; Glucose Metabolism Disorders
• Other Study ID Numbers: H-21037442

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No